MyFinsight
Home
Blog
About
Contact
Proceeds from issuance of
2033 notes /2031...
$632,500K
Proceeds from stock
option exercises, net...
$22,589K
Proceeds from common
stock issuances under...
$5,466K
Net cash provided by
financing activities
$549,892K
Canceled cashflow
$110,663K
Net increase
(decrease) in cash, cash...
$309,878K
Canceled cashflow
$240,014K
Repurchase of common stock
$82,500K
Issuance costs and
discounts associated with...
$12,796K
Repayments of deferred
royalty obligations
$11,293K
Repurchase of rsu shares to
satisfy tax withholding
$4,074K
Noncash interest
expense on deferred...
$39,873K
Stock-based compensation
$33,242K
Net loss from equity
method investments
-$18,283K
Accrued research and
development liabilities
$12,994K
Other liabilities
$4,617K
Amortization of debt discount
and issuance costs
$1,819K
Noncash lease expense
$1,466K
Depreciation and
amortization
$1,186K
Other noncash
adjustments, net
-$306K
Maturities of marketable
securities
$10,000K
Net cash used in
operating activities
-$197,279K
Net cash used in
investing activities
-$42,735K
Canceled cashflow
$113,786K
Canceled cashflow
$10,000K
Net loss
-$166,555K
Accounts receivable, net
$65,782K
Purchases of marketable
securities
$52,666K
Accrued compensation
and benefits
-$37,476K
Prepaid expenses and
other current assets
$18,845K
Accounts payable
-$7,170K
Inventories
$7,053K
Deferred revenue
-$2,379K
Change in fair value of
the embedded...
$2,158K
Operating lease
liabilities
-$1,852K
Other assets
$1,795K
Purchases of property and
equipment
$69K
Back
Back
Cash Flow
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)
source: myfinsight.com